Karuna Therapeutics, Inc.
KRTXNASDAQHealthcare
$329.83
+$0.09(+0.03%)
Market Cap$12.6B
P/E Ratio—
52W High$329.99
52W Low$158.375
Karuna Therapeutics, Inc. (KRTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KRTX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.65M | $10.64M | $36.96M | $0.00M | $0.00M |
| Cost of Revenue | $1.70M | $1.11M | $0.51M | $0.14M | $0.06M |
| Gross Profit | ($1.05M) | $9.53M | $36.46M | ($0.14M) | ($0.06M) |
| Gross Margin %(computed) | -160.09% | 89.55% | 98.63% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $364.10M | $224.25M | $128.20M | $43.41M | $24.54M |
| G&A Expenses | $131.33M | $76.07M | $52.62M | $28.41M | $20.87M |
| Total Operating Expenses | $495.43M | $300.31M | $180.82M | $71.82M | $45.41M |
| Operating Income | ($494.78M) | ($289.68M) | ($143.85M) | ($71.82M) | ($45.41M) |
| Operating Margin %(computed) | — | — | -389.17% | — | — |
| Interest Income | $61.18M | $14.18M | $0.50M | $3.31M | $2.53M |
| Interest Expense | $0.00M | $14.18M | $0.00M | $0.00M | $0.94M |
| Income Before Tax | ($433.01M) | ($274.92M) | ($143.80M) | ($68.51M) | ($43.96M) |
| Income Tax Expense | $0.67M | $1.42M | $0.01M | $0.04M | $0.89M |
| Net Income | ($433.68M) | ($276.34M) | ($143.81M) | ($68.55M) | ($44.84M) |
| Net Margin %(computed) | — | — | -389.04% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-11.73 | $-8.74 | $-4.94 | $-2.59 | $-3.75 |
| Wtd Avg Shares | 36.96M | 31.63M | 29.14M | 26.45M | 11.96M |
| EBITDA | ($493.08M) | ($259.63M) | ($143.15M) | ($68.51M) | ($42.88M) |
| EBITDA Margin %(computed) | — | — | -387.27% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Karuna Therapeutics, Inc. data
About Karuna Therapeutics, Inc. (KRTX) Income Statement
Karuna Therapeutics, Inc. (KRTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, KRTX reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -160.09%), and net income of ($0.43B) — a net profit margin of -66311.93%.
Frequently asked questions
KRTX · 4 questionsKaruna Therapeutics, Inc. (KRTX) reported revenue of $0.00B for 2023, down 93.9% year-over-year.
KRTX revenueKRTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09